168 related articles for article (PubMed ID: 15809205)
41. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
Hanrahan V; Currie MJ; Gunningham SP; Morrin HR; Scott PA; Robinson BA; Fox SB
J Pathol; 2003 Jun; 200(2):183-94. PubMed ID: 12754739
[TBL] [Abstract][Full Text] [Related]
42. Vascular endothelial growth factor receptor expression as a prognostic marker for survival in colorectal cancer.
Okita NT; Yamada Y; Takahari D; Hirashima Y; Matsubara J; Kato K; Hamaguchi T; Shirao K; Shimada Y; Taniguchi H; Shimoda T
Jpn J Clin Oncol; 2009 Sep; 39(9):595-600. PubMed ID: 19535387
[TBL] [Abstract][Full Text] [Related]
43. Serum vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 as prognostic biomarkers for uterine cervical cancer.
Sawada M; Oishi T; Komatsu H; Sato S; Chikumi J; Nonaka M; Kudoh A; Osaku D; Harada T
Int J Clin Oncol; 2019 Dec; 24(12):1612-1619. PubMed ID: 31236742
[TBL] [Abstract][Full Text] [Related]
44. Analysis of circulating vascular endothelial growth factor and its soluble receptors in patients with different forms of chronic urticaria.
Jagodzinska J; Polaniak R; Birkner E; Kasperska-Zajac A
Biomed Res Int; 2015; 2015():578383. PubMed ID: 25756047
[TBL] [Abstract][Full Text] [Related]
45. Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma.
Al-Moundhri MS; Al-Shukaili A; Al-Nabhani M; Al-Bahrani B; Burney IA; Rizivi A; Ganguly SS
World J Gastroenterol; 2008 Jun; 14(24):3879-83. PubMed ID: 18609713
[TBL] [Abstract][Full Text] [Related]
46. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
[TBL] [Abstract][Full Text] [Related]
47. VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity.
Pieh C; Agostini H; Buschbeck C; Krüger M; Schulte-Mönting J; Zirrgiebel U; Drevs J; Lagrèze WA
Br J Ophthalmol; 2008 May; 92(5):689-93. PubMed ID: 18408080
[TBL] [Abstract][Full Text] [Related]
48. Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC.
Jantus-Lewintre E; Sanmartín E; Sirera R; Blasco A; Sanchez JJ; Tarón M; Rosell R; Camps C
Lung Cancer; 2011 Nov; 74(2):326-31. PubMed ID: 21481963
[TBL] [Abstract][Full Text] [Related]
49. High level of circulating endothelial progenitor cells positively correlates with serum vascular endothelial growth factor in patients with renal cell carcinoma.
Yang B; Gu W; Peng B; Xu Y; Liu M; Che J; Geng J; Zheng J
J Urol; 2012 Dec; 188(6):2055-61. PubMed ID: 23088990
[TBL] [Abstract][Full Text] [Related]
50. Relationship between circulating vascular endothelial growth factor and its soluble receptors in adults with dengue virus infection: a case-control study.
Seet RC; Chow AW; Quek AM; Chan YH; Lim EC
Int J Infect Dis; 2009 Sep; 13(5):e248-53. PubMed ID: 19261502
[TBL] [Abstract][Full Text] [Related]
51. Clinical significance of pretreatment serum levels of VEGF and its receptors, IL- 8, and their prognostic value in type I and II endometrial cancer patients.
Kotowicz B; Fuksiewicz M; Jonska-Gmyrek J; Berezowska A; Radziszewski J; Bidzinski M; Kowalska M
PLoS One; 2017; 12(10):e0184576. PubMed ID: 28991928
[TBL] [Abstract][Full Text] [Related]
52. Expression of vascular endothelial growth factor and vascular endothelial growth factor receptors 1 and 2 in invasive breast carcinoma: prognostic significance and relationship with markers for aggressiveness.
Dhakal HP; Naume B; Synnestvedt M; Borgen E; Kaaresen R; Schlichting E; Wiedswang G; Bassarova A; Holm R; Giercksky KE; Nesland JM
Histopathology; 2012 Sep; 61(3):350-64. PubMed ID: 22690749
[TBL] [Abstract][Full Text] [Related]
53. Soluble VEGF/sFLt1 ratio is an independent predictor of AML patient out come.
Aref S; El Sherbiny M; Goda T; Fouda M; Al Askalany H; Abdalla D
Hematology; 2005 Apr; 10(2):131-4. PubMed ID: 16019458
[TBL] [Abstract][Full Text] [Related]
54. Serum levels of vascular endothelial growth factor and its receptors in patients with severe autism.
Emanuele E; Orsi P; Barale F; di Nemi SU; Bertona M; Politi P
Clin Biochem; 2010 Feb; 43(3):317-9. PubMed ID: 19850021
[TBL] [Abstract][Full Text] [Related]
55. The VEGF receptor, neuropilin-1, represents a promising novel target for chronic lymphocytic leukemia patients.
Piechnik A; Dmoszynska A; Omiotek M; Mlak R; Kowal M; Stilgenbauer S; Bullinger L; Giannopoulos K
Int J Cancer; 2013 Sep; 133(6):1489-96. PubMed ID: 23447383
[TBL] [Abstract][Full Text] [Related]
56. Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by leukemia-derived Ang2 and VEGF.
Maffei R; Martinelli S; Castelli I; Santachiara R; Zucchini P; Fontana M; Fiorcari S; Bonacorsi G; Ilariucci F; Torelli G; Marasca R
Leuk Res; 2010 Mar; 34(3):312-21. PubMed ID: 19616847
[TBL] [Abstract][Full Text] [Related]
57. Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells.
Farahani M; Treweeke AT; Toh CH; Till KJ; Harris RJ; Cawley JC; Zuzel M; Chen H
Leukemia; 2005 Apr; 19(4):524-30. PubMed ID: 15674425
[TBL] [Abstract][Full Text] [Related]
58. Reduced serum vascular endothelial growth factor receptor-2 (sVEGFR-2) and sVEGFR-1 levels in gastric cancer patients.
Kikuchi S; Obata Y; Yagyu K; Lin Y; Nakajima T; Kobayashi O; Kikuichi M; Ushijima R; Kurosawa M; Ueda J
Cancer Sci; 2011 Apr; 102(4):866-9. PubMed ID: 21219538
[TBL] [Abstract][Full Text] [Related]
59. Different cascades in the signaling pathway of two vascular endothelial growth factor (VEGF) receptors for the VEGF-mediated murine hepatocellular carcinoma development.
Yoshiji H; Noguchi R; Kuriyama S; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Uemura M; Fukui H
Oncol Rep; 2005 May; 13(5):853-7. PubMed ID: 15809749
[TBL] [Abstract][Full Text] [Related]
60. The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab.
Smerdel MP; Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
Gynecol Oncol; 2010 Aug; 118(2):167-71. PubMed ID: 20471067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
